Deciphera Pharmaceuticals (DCPH) IPO Opens Up 18%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Brazil's Bolsonaro, Lula face off in first debate as supporters fill streets
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering
September 27, 2017 9:49 PM EDTWALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share for aggregate gross proceeds of $127,500,000. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price. The shares are... More



